Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Biogen Inc.
Type
Public
Traded as NASDAQ: BIIB
NASDAQ-100 Component
S&P 500 Component
Industry Biotechnology
Founded 1978 (from merger)
Headquarters Cambridge, Massachusetts, U.S.
Key people
Stelios Papadopoulos, Chairman
George A. Scangos, CEO
Products Alprolix, Avonex, Eloctate, Fampyra, Gazyva*, Plegridy, Rituxan*, Tecfidera, Tysabri
Revenue Increase US$ 9.703 billion (2014)
Operating income
Increase US$ 3.972 billion (2014)
Net income
Increase US$ 2.941 billion (2014)
Total assets Increase US$ 14.31 billion (2014)
Total equity Increase US$ 10.80 billion (2014)
Number of employees
7,550 (December 2014)
Website www.biogen.com

Biogen is an American global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Biogen
(Founded 1978)

IDEC Pharmaceuticals

Convergence Pharmaceuticals
(Acq 2015)

Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.

Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.

Acquired in acquisition of Fumapharm AG in 2006.

Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.

Anti-TNF Refractory Rheumatoid Arthritis

2006

Currently commercialized by Roche and its subsidiary, Genentech.

Investment goal date:
Dividends reinvested
Biogen Inc. BIIB report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-23
--
--
Q4 2017
2018-01-27
--
--
Q3 2017
2017-10-24
6.3100
5.7900
Q2 2017
2017-07-25
5.0400
4.0700
Q1 2017
2017-04-25
5.2000
3.4600
Q4 2016
2017-01-26
5.0400
2.9900
Q3 2016
2016-10-26
5.1900
4.7100
Q2 2016
2016-07-21
5.2100
4.7900
Q1 2016
2016-04-21
4.7900
4.4300
Q4 2015
2016-01-27
4.5000
3.7700
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ALLIANCEBERNSTEIN L.P.
2937319
BlackRock Fund Advisors
5298451
BlackRock Inc.
17692259
BlackRock Institutional Trust Company, N.A.
6102240
Clearbridge Investments, LLC
9121025
FMR LLC
5542590
Invesco Ltd.
4136946
JPMORGAN CHASE & CO
3617561
NORTHERN TRUST CORP
2793765
PRICE T ROWE ASSOCIATES INC /MD/
8118191
PRIMECAP MANAGEMENT CO/CA/
15477424
SANDS CAPITAL MANAGEMENT, LLC
2475937
STATE STREET CORP
9580383
Vanguard Group, Inc
14352490
WELLINGTON MANAGEMENT CO LLP
5712355
Major Shareholders
Name Relationship
Total Shares
Holding stocks
DORSA CAROLINE
0.0100% (18172)
BIIB / ILMN / NTLA / PEG /
WILLIAMS DOUGLAS E
0.0100% (11817)
PAPADOPOULOS STELIOS
0.0100% (19946)
BGMD / BIIB / EXEL / RGLS /
SCANGOS GEORGE A
0.0200% (54936)
A / BIIB / EXEL /
PANGIA ROBERT W
0.0100% (17707)
BIIB /
YOUNG WILLIAM
0.0100% (18509)
BIIB / NSTG /
ALEXANDER SUSAN H
0.0100% (22258)
BIIB / IVC /
Rowinsky Eric K
0.0100% (14144)
DENNER ALEXANDER J
0.1600% (383858)
% ()